Live Breaking News & Updates on Early Outcomes

Emergency physicians use heparin alternative to treat vaccine-induced blood clot
A new case report, detailed in
Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance.
An otherwise healthy female patient in her 40s came to the emergency department at UCHealth University of Colorado Hospital twelve days after receiving the Johnson & Johnson vaccine with a headache, dizziness, and vision changes.
Related Stories
The patient was treated on April 13, 2021, the same day that the Centers for Disease Control and Prevention (CDC) announced a pause in the administration of the Johnson & Johnson vaccine. CDC guidance recommended treatment with heparin alternatives but did not recommended any specific alternative in that announcement. ....

United States , R Todd Clark , Emily Henderson , Centers For Disease , Uchealth University Of Colorado Hospital , University Of Colorado School Medicine , Study Lead Co , Emergency Medicine , Disease Control , Colorado Hospital , Todd Clark , Study Lead Co Author , Assistant Professor , Colorado School , Early Outcomes , Bivalirudin Therapy , Thrombotic Thrombocytopenia , Cerebral Venous Sinus Thrombosis , Emergency Medicine , ஒன்றுபட்டது மாநிலங்களில் , எமிலி ஹென்டர்சன் , மையங்கள் க்கு நோய் , உச்சோல்த் பல்கலைக்கழகம் ஆஃப் கொலராடோ மருத்துவமனை , பல்கலைக்கழகம் ஆஃப் கொலராடோ பள்ளி மருந்து , படிப்பு வழி நடத்து இணை , அவசரம் மருந்து ,